Septal alcoholization in obstructive hypertrophic cardiomyopathy. Septal staining with saline solution as an alternative to echo-enhancers
DOI:
https://doi.org/10.37615/retic.v8n1a3Keywords:
ventricular outflow obstruction, transesophageal echocardiography, heart failureAbstract
Hypertrophic cardiomyopathy (HCM) is a myocardial disease caused by monogenic sarcomeric mutations and characterized by unexplained hypertrophy of the left ventricle. When medical treatment is ineffective, a therapeutic alternative is septal thickness reduction, with surgical septal myomectomy being the choice when performed in high-volume and experienced centers. However, another less invasive option is septal alcoholization. We present two patients—with repeated hospitalizations for heart failure—who underwent septal alcoholization as an alternative to surgical myomectomy. The objective is to highlight and explain the appropriate selection of septal branches, using the injection of agitated physiological solution, without the need for high-cost and difficultto-access echo-enhancers.
Downloads
Metrics
References
Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology/ American heart association Joint committee on clinical Practice guidelines. Circulation. 2020;142(25):e558-e631. doi: https://doi.org/10.1161/CIR.0000000000000938
Pérez-Sánchez I, Romero-Puche A, García-Molina Sáez E, et al. Factors Influencing the Phenotypic Expression of Hypertrophic Cardiomyopathy in Genetic Carriers. Rev Esp Cardiol (Engl Ed). 2018;71(3):146-154. doi: https://doi.org/10.1016/j.rec.2017.06.002
Pasipoularides A. Genomic translational research: Paving the way to individualized cardiac functional analyses and personalized cardiology. Int J Cardiol. 2017;230:384-401. doi: https://doi.org/10.1016/J.ijcard.2016.12.097
Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2011;58(25):e212-60. doi: https://doi.org/10.1016/j.jacc.2011.06.011
Harmon KG, Drezner JA, Wilson MG, Sharma S. Incidence of sudden cardiac death in athletes: a state-of-the-art review. Heart. 2014;100(16):1227-34. doi: https://doi.org/10.1136/heartjnl-2014-093872.rep
Hegde SM, Lester SJ, Solomon SD, et al. Effect of Mavacamten on echocardiographic features in symptomatic patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2021;78(25):2518-2532. doi: https://doi.org/10.1016/j.jacc.2021.09.1381
Olivotto I, Oreziak A, Barriales-Villa R, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020;396(10253):759-769. doi: 10.1016/S0140-6736(20)31792-X
Elliott PM, Gimeno JR, Tomé MT, et al. Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy. Eur Heart J. 2006;27(16):1933-41. doi: https://doi.org/10.1093/eurheartj/ehl041
Ho CY, Mealiffe ME, Bach RG, et al. Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2020;75(21):2649-2660. doi: https://doi.org/10.1016/j.jacc.2020.03.064
Maron BJ, Desai MY, Nishimura RA, et al. Management of Hypertrophic Cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol. 2022;79(4):390-414. doi: https://doi.org/10.1016/j.jacc.2021.11.021
Hassenstein P, Storch HH, Schmitz W. Results of electrical pacing in patients with hypertrophic obstruction cardiomyopathy. Thoraxchir Vask Chir. 1975;23(5):496-8. doi:https://doi.org/10.1055/s-0028-1097017
Woo A, Williams WG, Choi R, et al. Clinical and echocardiographic determinants of long-term survival after surgical myectomy in obstructive hypertrophic cardiomyopathy. Circulation. 2005;111(16):2033-41. doi: https://doi.org/10.1161/01.CIR.0000162460.36735.71
Ferrazzi P, Spirito P, Iacovoni A, et al. Transaortic chordal cutting: mitral valve repair for obstructive hypertrophic cardiomyopathy with mild septal hypertrophy. J Am Coll Cardiol. 2015;66(15):1687-96. doi: https://doi.org/10.1016/j.jacc.2015.07.069
Sorajja P, Valeti U, Nishimura RA, et al. Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation. 2008;118(2):131-9. doi: https://doi.org/10.1161/CIRCULATIONAHA.107.738740
Liebregts M, Faber L, Jensen MK, et al. Outcomes of Alcohol Septal Ablation in Younger Patients With Obstructive Hypertrophic Cardiomyopathy. JACC Cardiovasc Interv. 2017;10(11):1134-1143. doi: https://doi.org/10.1016/j.jcin.2017.03.030
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Miguel Ángel Tibaldi, Mayra Florencia Valdez, Natalia Romero, Judith Mailén Vicentin, Hugo Londero, Guillermo Pacheco
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
RETIC is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license https://creativecommons.org/licenses/by-nc-nd/4.0 which allows sharing, copying and redistribution of the material in any medium or format, under the following terms:
- Attribution: you must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests that the licensor endorses you or your use.
- Non-commercial: you may not use the material for commercial purposes.
- No Derivatives: if you remix, transform or build upon the material, you may not distribute the modified material.
- No Additional Restrictions: you may not apply legal terms or technological measures that legally restrict others from doing anything permitted by the license.
